An Open-Label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib Versus Sunitinib as First-Line Followed by Second-Line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Trial Profile

An Open-Label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib Versus Sunitinib as First-Line Followed by Second-Line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Everolimus (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms RECORD-3
  • Sponsors Novartis
  • Most Recent Events

    • 10 Feb 2018 Results assessing mutation status integration into the MSKCC model using two large clinical trial datasets (COMPARZ and RECORD3; n=487) presented at the 2018 Genitourinary Cancers Symposium
    • 29 Jan 2018 Results (n=471) assessing final overall survival analysis for secondary endpoints were, published in the Annals of Oncology.
    • 18 Feb 2017 Results (n=128) assessing tumor genomic analysis presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top